---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-012620"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:22:40.403330+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology Q1 2022: cash $129.4M; mCRC trial shows improved ORR/PFS vs historical controls

## Summary
- Cash, equivalents & short-term investments ~$129.4M as of Mar 31, 2022; net cash used in ops $10.2M.
- R&D expense $7.2M (up $3.9M YoY); SG&A $3.9M (up $1.7M YoY) on higher CMC, headcount, stock comp.
- Phase 1b/2 mCRC: 34% initial ORR, 29% confirmed at RP2D (15 mg/m²) vs historical 5-13%; mPFS 9.4 months across all doses.
- Phase 2 mCRPC: 75% disease control at 12 weeks in highest dose-density arm; mutations in PTEN/MTOR linked to response.
- Preclinical: onvansertib+olaparib showed significant survival benefit vs each alone in PARPi-resistant ovarian PDX models.

## SEC filing metadata
- accession: 0001628280-22-012620
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828022012620/0001628280-22-012620-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828022012620/crdf-20220505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-012620
- JSON: https://secwatch.observer/filing/0001628280-22-012620.json
- Plain text: https://secwatch.observer/filing/0001628280-22-012620.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.